EPISK-17 is under clinical development by EpiPharm and currently in Phase II for Dermatological Disorders. According to GlobalData, Phase II drugs for Dermatological Disorders have a 20% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how EPISK-17’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
EPISK-17 is under development for the treatment of seborrheic keratosis. It is an artemisinin derivative administered through topical route.
EpiPharm is a bio pharmaceutical company that develops and markets home topical products for the treatment of benign skin tumours and hyperpigmentation disorders. The company’s pipeline products include EPI-NO6, a topical solution used in the treatment of nevi, age and sun spots; and EPI-SK14, a non-invasive topical solution used to treat seborrheic keratosis. It also provides EPI-M13, a non-invasive topical solution used in the treatment of melasma; and EPI-C08 used to treat the age and sun spots. EpiPharm also develops treatments for other indications through line extensions of its proprietary discoveries. The company works in collaboration with various drug and cosmetic development and manufacturing companies. EpiPharm is headquartered in Arlesheim, Switzerland.
For a complete picture of EPISK-17’s drug-specific PTSR and LoA scores, buy the report here.